![AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says | Fierce Pharma AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1627065958/Astrazeneca%20.jpg/Astrazeneca%20.jpg?VersionId=0SwzcAMXxVbrlhBQSgVZfGPGnvYHeDyb)
AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says | Fierce Pharma
![Hematology Reports | Free Full-Text | Analysis of Costs per Responder in US Adults with Paroxysmal Nocturnal Hemoglobinuria with a Suboptimal Response to Prior Eculizumab Treatment Hematology Reports | Free Full-Text | Analysis of Costs per Responder in US Adults with Paroxysmal Nocturnal Hemoglobinuria with a Suboptimal Response to Prior Eculizumab Treatment](https://www.mdpi.com/hematolrep/hematolrep-15-00060/article_deploy/html/images/hematolrep-15-00060-g001.png)
Hematology Reports | Free Full-Text | Analysis of Costs per Responder in US Adults with Paroxysmal Nocturnal Hemoglobinuria with a Suboptimal Response to Prior Eculizumab Treatment
![SOLIRIS (Eculizumab) – Un nou medicament pentru miastenia generalizata refractara – Asociatia Nationala Miastenia Gravis Romania SOLIRIS (Eculizumab) – Un nou medicament pentru miastenia generalizata refractara – Asociatia Nationala Miastenia Gravis Romania](https://miastenie.ro/wp-content/uploads/2016/02/soliris-1200x480.jpg)
SOLIRIS (Eculizumab) – Un nou medicament pentru miastenia generalizata refractara – Asociatia Nationala Miastenia Gravis Romania
![Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands | The European Journal of Health Economics Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands | The European Journal of Health Economics](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10198-022-01556-5/MediaObjects/10198_2022_1556_Fig1_HTML.png)
Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands | The European Journal of Health Economics
![After discount, U.K. price watchdog gives a nod to Alexion's Ultomiris for a second rare blood disorder | Fierce Pharma After discount, U.K. price watchdog gives a nod to Alexion's Ultomiris for a second rare blood disorder | Fierce Pharma](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1621456453/Ultomiris.jpg/Ultomiris.jpg?VersionId=2LhQR4uL_8mEWTw_tbG.7boH7NBinikg)
After discount, U.K. price watchdog gives a nod to Alexion's Ultomiris for a second rare blood disorder | Fierce Pharma
![Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria | PharmacoEconomics Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria | PharmacoEconomics](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs40273-020-00929-z/MediaObjects/40273_2020_929_Fig2_HTML.png)
Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria | PharmacoEconomics
![Soliris Eculizumab 300mg at 44840.00 INR in Bengaluru, Karnataka | Kushal Hearth Care Medical Center Soliris Eculizumab 300mg at 44840.00 INR in Bengaluru, Karnataka | Kushal Hearth Care Medical Center](https://tiimg.tistatic.com/fp/1/006/948/soliris-eculizumab-300mg-049.jpg)